首页 | 本学科首页   官方微博 | 高级检索  
     

参慈胶囊联合顺铂抑制小鼠Lewis肺癌组织血管生成的机制研究
引用本文:徐立群,张荣华,薛兴阳,邬晓东,傅淑平,蔡宇,梁昆,陈锐深. 参慈胶囊联合顺铂抑制小鼠Lewis肺癌组织血管生成的机制研究[J]. 中国病理生理杂志, 2010, 26(12): 2347-2350. DOI: 10.3969/j.issn.1000-4718.2010.12.012
作者姓名:徐立群  张荣华  薛兴阳  邬晓东  傅淑平  蔡宇  梁昆  陈锐深
作者单位:1. 广州医学院附属肿瘤医院, 广州医学院肿瘤研究所, 广东 广州 510095;
2. 暨南大学药学院, 广东 广州 510632;
3. 香港大学中医药学院, 香港;
4. 广州中医药大学第一附属医院, 广东 广州 510405
基金项目:广东省中医药管理局资助项目
摘    要:目的:探讨参慈胶囊及顺铂对Lewis肺癌组织生长及血管生成的抑制作用。方法:将40只C57BL/6小鼠自接种Lewis肺癌瘤株细胞建立实体瘤模型,随机分为参慈胶囊组、参慈胶囊+顺铂组、顺铂组、模型组。模型组予等量生理盐水,其余各组荷瘤小鼠均用药21 d,测量肿瘤重量并计算抑瘤率,采用免疫组化技术检测血管内皮生长因子(VEGF)、微血管密度(MVD)表达情况;采用实时荧光定量PCR(FQ-PCR)技术检测Lewis肺癌荷瘤小鼠癌细胞表达血管内皮生长因子受体-2(KDR)mRNA的情况。结果:(1)在抑瘤率方面,参慈胶囊+顺铂组抑瘤率明显高于其它3组,差异显著(P0.01)。(2)参慈胶囊+顺铂组能降低Lewis肺癌组织VEGF、KDR的表达及MVD的形成,差异显著(P0.01)。结论:(1)参慈胶囊联合顺铂能抑制Lewis肺癌组织生长及血管生成,二者联用具有相加或者协同效应;(2)下调VEGF及其受体KDR的表达,可能是二者联合抗肿瘤血管生成的机制之一。

关 键 词:参慈胶囊  血管生成  微血管密度  
收稿时间:2010-06-03

Inhibitory effect of Shenci capsule in combination with DDP on angiogenesis in mice with Lewis lung cancer
XU Li-qun,ZHANG Rong-hua,XUE Xing-yang,WU Xiao-dong,FU Shu-ping,CAI Yu,LIANG Kun,CHEN Rui-shen. Inhibitory effect of Shenci capsule in combination with DDP on angiogenesis in mice with Lewis lung cancer[J]. Chinese Journal of Pathophysiology, 2010, 26(12): 2347-2350. DOI: 10.3969/j.issn.1000-4718.2010.12.012
Authors:XU Li-qun  ZHANG Rong-hua  XUE Xing-yang  WU Xiao-dong  FU Shu-ping  CAI Yu  LIANG Kun  CHEN Rui-shen
Affiliation:1. Affiliated Tumor Hospital of Guangzhou Medical College, Tumor Institute of Guangzhou Medical College, Guangzhou 510095, China;
2. Pharmacy College of Jinan University, Guangzhou 510632, China;
3. Chinese Medicine School of The University of Hong Kong, Hong Kong, China;
4. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
Abstract:AIM: To investigate the inhibitory effect of Shenci capsule, a Chinese medicine, in combination with cisplatin (DDP) on the tumor growth and angiogenesis in mouse Lewis lung cancer.METHODS: Forty mice with Lewis lung cancer were randomly divided into 4 groups: Shenci capsule group, Shenci capsule in combination with DDP group, DDP group and control group. Shenci capsule, Shenci capsule in combination with DDP,DDP and sodium chloride wene given, respectively. After 21 days, the weight of subcutaneous tumors was measured, and the tumor inhibition rate was calculated. The microvessel density (MVD) and the protein level of vascular endothelial growth factor (VEGF) were detected by immunohistochemical(IHC) staining. The mRNA expression levels of kinase insert domain-containing receptor (KDR) and the receptor of VEGF were detected by FQ-PCR. RESULTS: The tumor growth inhibitory rate in Shenci capsule in combination with DDP group (63.99%) was higher than that in Shenci capsule group, DDP group and control group (P<0.01). The tumor MVD, VEGF protein and KDR mRNA expression level in Shenci capsule in combination with DDP group were lower than those in the above three groups (P<0.01). CONCLUSION: Shenci capsule in combination with DDP have addition or synergistic effects to inhibit the tumor growth and angiogenesis in mouse Lewis lung cancer. Down-regulation of VEGF and its receptor KDR may be one of the mechanisms that combined use of these two drugs for inhibiting angiogenesis.
Keywords:Shenci capsule  Angiogenesis  Microvessel density
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号